Sector
PharmaceuticalsOpen
₹108.3Prev. Close
₹108.3Turnover(Lac.)
₹10.78Day's High
₹108.3Day's Low
₹106.852 Week's High
₹18652 Week's Low
₹86.2Book Value
₹157.18Face Value
₹10Mkt Cap (₹ Cr.)
632.23P/E
6.03EPS
18.06Divi. Yield
014 Aug 2024
12:00 AM
BookCloser
28 Jun 2024
12:00 AM
EGM
2 Sep 2024
12:00 AM
AGM
Announcement Date: 02 Sep, 2024
6 Nov 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 59.09 | 59.81 | 59.81 | 59.81 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 863.16 | 615.54 | 572.75 | 578.89 |
Net Worth | 922.25 | 675.35 | 632.56 | 638.7 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 856.57 | 751.83 | 731.29 | 693.71 |
yoy growth (%) | 13.93 | 2.8 | 5.41 | 8.6 |
Raw materials | -424.99 | -378.84 | -375.06 | -395.81 |
As % of sales | 49.61 | 50.38 | 51.28 | 57.05 |
Employee costs | -104.16 | -100.37 | -89.3 | -71.61 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 16.11 | -19.56 | 30.51 | -50.85 |
Depreciation | -87.29 | -90.05 | -86.61 | -88.25 |
Tax paid | -20.51 | -1.22 | -10.95 | 16.46 |
Working capital | 24.4 | 224.01 | -12.39 | -206.93 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.93 | 2.8 | 5.41 | 8.6 |
Op profit growth | 27.14 | 11.71 | 20.97 | -3.11 |
EBIT growth | 32.31 | 49.44 | 56.9 | -0.94 |
Net profit growth | -78.84 | -217.94 | -144.36 | -32.51 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 1,280.9 | 1,207.31 | 1,038.73 | 891.34 | 779.64 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,280.9 | 1,207.31 | 1,038.73 | 891.34 | 779.64 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 431.96 | 33.5 | 43.5 | 22.7 | 33.4 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,819 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,782.35 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.6 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.75 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,399.45 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
N R Munjal
Joint Managing Director
Himanshu Jain
Company Sec. & Compli. Officer
Pradeep Verma
Executive Director
Rishav Mehta
Independent Director
S P Sharma
Independent Director
Neerja Chathley
Independent Director
Ashwani K Vig
Executive Director
Sahil Munjal
Independent Director
Rajendra Kumar Gupta
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ind-Swift Laboratories Ltd
Summary
Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, India. The Company is one of the leading manufacturers of APIs catering to global and domestic formulators. Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards. Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide.Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation. Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company. The company commenced their production in the year 1997. Over a short period, the company has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries.In the year 1997, the company went public and concentrated on the manufacture of Active Pharmaceutical Ingredients (API). In the year 1998-99, they launched two molecules, Clarithromycin and Roxithromycin. Their in-house R&D developed Clarithromycin Granules for the first time in India.In the year 2000, the company developed a new drug namely, Astrovastatin. In addition, they entered into an agreement with eight international pharmaceutical companies to source their requirements fo
Read More
What is the Ind-Swift Laboratories Ltd share price today?
The Ind-Swift Laboratories Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹107 today.
What is the Market Cap of Ind-Swift Laboratories Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ind-Swift Laboratories Ltd is ₹632.23 Cr. as of 24 Dec ‘24
What is the PE and PB ratio of Ind-Swift Laboratories Ltd?
The PE and PB ratios of Ind-Swift Laboratories Ltd is 6.03 and 0.64 as of 24 Dec ‘24
What is the 52 Week High and Low of Ind-Swift Laboratories Ltd?
The 52-week high/low is the highest and lowest price at which a Ind-Swift Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ind-Swift Laboratories Ltd is ₹86.2 and ₹186 as of 24 Dec ‘24
What is the CAGR of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's CAGR for 5 Years at 36.60%, 3 Years at 16.66%, 1 Year at 9.24%, 6 Month at -9.64%, 3 Month at -18.59% and 1 Month at 8.49%.
What is the shareholding pattern of Ind-Swift Laboratories Ltd?
The shareholding pattern of Ind-Swift Laboratories Ltd is as follows:
Promoters - 42.00 %
Institutions - 1.59 %
Public - 56.41 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
